CD38 and T-cell non-Hodgkin lymphoma: Single targeting CD38-CAR T and dual targeting tandem CD38/latent membrane protein-1-CAR T all showed promising cytotoxicity against NK/T-cell lymphoma in in vitro and in vivo pre-clinical experiments (178).